SUMMARY BackgroundProton pump inhibitor-responsive oesophageal eosinophilia (PPI-REE) is common in patients with suspected eosinophilic oesophagitis (EoE). However, the long-term efficacy of PPIs and the best maintenance doses are yet to be defined.

Background and objective: Eosinophilic esophagitis (EoE) is an increasingly prevalent chronic inflammatory disease of the esophagus with an immunoallergic etiology. Few studies have been published on EoE in children and adolescents. The objective of this study was to analyze the demographic, clinical, serologic, endoscopic-histologic, and atopic characteristics of pediatric patients with EoE and to identify atopic and digestive comorbidities. Methods: We conducted a prospective observational study in children and adolescents (<16 years) assessed in a specialized multidisciplinary EoE unit in a tertiary referral hospital in a central region of Spain between 2011 and 2015. Results: Thirty-five patients were included in the study. Twenty-eight (80%) were male. The mean age was 9.6 years, 83% were atopic, and 28% reported a family history of atopy. The most common symptom was dysphagia (51%). Eosinophilia was detected in the blood of 60% of patients. Eosinophil cationic protein and total IgE were elevated in 88% and 77% of patients, respectively. The most frequent endoscopic finding was linear grooves (57%). Skin tests with aeroallergens were positive in 82% of patients (pollen 62% and food 60%). The main atopic comorbidities were asthma (48%) and rhinoconjunctivitis (37%). Digestive diseases were more often associated with gastritis and Helicobacter pylori infection (17%). Conclusions: Our results are similar to those previously reported. EoE is more common in boys and in individuals with a history of atopy and sensitization to airborne allergens and food. These results support the consideration of EoE as an atopic disease and underline the important role of allergists in early diagnosis and treatment.

Palabras clave: Inmunoterapia frente a veneno. Veneno de avispa. Trastornos autoinmunológicos.Venom immunotherapy (VIT) is the only highly effective way of treating patients with hymenoptera venom allergy (HVA). The most serious anaphylactic symptoms of HVA (HVA-SYS IVo) are life-threatening, thus making their occurrence an unconditional recommendation for VIT. Yet, VIT is contraindicated in immune-mediated inflammatory diseases.We present the case of a 55-year-old woman with autoinflammatory neurological disease (initially diagnosed with relapsing remitting multiple sclerosis) who received VIT following an anaphylactic reaction (SYS-IVo) to wasp sting (Vespula germanica). Allergy tests showed the presence of specific IgE antibodies to wasp venom (intradermal test at 0.001 µg/mL, 12×12 mm; sIgE class 2). The basal serum tryptase concentration was normal. Her past medical history included gastrointestinal reflux, mild gastritis, allergy to ketoprofen and metamizole sodium, and seronegative spondyloarthropathy. At the age of 50, she was diagnosed with remitting-relapsing multiple sclerosis. Her first symptoms of neurological damage were mild facial weakness, mild instability with the eyes closed in the Romberg test, and clumsy movements of the left hand. Magnetic resonance imaging (MRI) was performed twice and revealed multiple hyperintense areas that were considered demyelinating lesions. The cerebrospinal fluid study showed intrathecal production of immunoglobulins 1.75 [normal range,). Visual evoked potentials were normal. Lyme disease was excluded. The patient was treated with intravenous methylprednisolone (Solu-Medrol, 1000 mg/d over 5 days) during 3 exacerbations of the disease. Progression in her disability was measured using the Kurtzke Expanded Disability Status Scale (EDSS). Her initial EDSS was 1.5, which rose to 4.0 after the last exacerbation of the disease.The patient met the clinical and immunological criteria for VIT. Another reason in support of the decision to administer VIT was the patient's physical disability, which might have hindered attempts to avoid a sting, especially given that she lives in an area with high exposure to stinging insects. The decision to start VIT was made despite the hitherto accepted belief that autoimmunological diseases constitute a contraindication to immunotherapy. At the time the patient qualified for VIT, her condition was stable, with no new active neurological symptoms.No complications were recorded during the induction phase (ultrarush; Pharmalgen, ALK-Abelló) and a complete 5-year course of VIT. There were no local or systemic allergic reactions. Neurological symptoms did not intensify, and no new symptoms appeared. The patient did not experience exacerbation of her neurological disease; the EDSS score remained unchanged. The findings in subsequent MRI examinations of the brain were stable, with no new lesions. The MRI revealed no lesions in the temporal lobes or posterior fossa structures and no juxtacortical lesions (Figure, A). However, numerous, small,...

No abstract

Palabras clave: Crisantemo. Inhalante. Dermatitis ocupacional de contacto. Dermatitis de contacto por proteínas. nSal k 1.